Search
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[L40739] Patient T-cells are reprogrammed with a transgene encoding a specific chimeric antigen receptor (CAR) which features two BCMA-targeting single-domain antibodies. … Multiple myeloma is a malignancy involving the plasma cells of the bone marrow.
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.[A260286] … [A260286] Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012.
Quazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitIt was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIts benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. … It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Categories: Mineralocorticoid Receptor Antagonists, Mineralocorticoid (Aldosterone) Receptor AntagonistsEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Antazoline
go.drugbank.com/drugs/DB08799ApprovedIt is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.
Pentostatin
go.drugbank.com/drugs/DB00552ApprovedInvestigationalThe drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMore specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels … Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand.
Categories: Growth Hormone Secretagogue Receptor Agonist, Growth Hormone Secretagogue Receptor AgonistsBenzthiazide
go.drugbank.com/drugs/DB00562ApprovedBenzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). … Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity.
Synonyms: 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide